Analyst consensus rating
United Therapeutics Analyst Rating: Buy
UTHR is rated Buy by 12 analysts with a $664.33 target. As of 2026-08-29.
Direct answer
United Therapeutics's consensus rating is Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $664.33.
Forecast evidence checked August 29, 2026.
Get free United Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $515.46
- Average price target
- $664.33
- High price target
- $725.00
- Low price target
- $515.00
- Low target gap
- -0.1%
- Target upside
- +28.9%
- High target gap
- +40.7%
- Target range width
- 40.7%
- Consensus rating
- Buy
- Analysts
- 12
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for United Therapeutics?
United Therapeutics has a verified Buy consensus. The same dataset has an average price target of $664.33.
How far are United Therapeutics's low and high targets from the recorded price?
The low target implies -0.1%, while the high target implies +40.7%.
How many analysts are included in United Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is United Therapeutics's target upside or downside calculated?
The average target of $664.33 is divided by the recorded price of $515.46, then one is subtracted to produce +28.9%. This does not guarantee a future return.
When was United Therapeutics's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.